Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraarterial Cetuximab for Recurrent HNSCC
NCT02438995Phase 1Terminated
- Sponsor
- Northwell Health
- Start
- May 2015
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of KL-140 in head and neck squamous cell carcinoma (HNSCC) and adenoid cystic carcinoma (ACC) (2 arms), sponsored by Northwell Health. Primary endpoints: Maximum Tolerated Dose at 30 days and Frequency of Toxicities at 30 days. Started May 2015; status: terminated.
02
Drugs
KL-140
03
Conditions
head and neck squamous cell carcinoma (HNSCC)adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT02438995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02438995.